Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
Omics International publishes 37 Open Access Articles in 4 International Journals it has 13 Upcoming Conferences and 10 Previous Conferences with 218 Conference Proceedings and 13 National symposiums so far in the field.
Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative diseases including ALS, Parkinson's, Alzheimer's, and Huntington's occur as a result of neurodegenerative processes. Such diseases are incurable, resulting in progressive degeneration and/or death of neuron cells. As research progresses, many similarities appear that relate these diseases to one another on a sub-cellular level. Discovering these similarities offers hope for therapeutic advances that could ameliorate many diseases simultaneously. There are many parallels between different neurodegenerative disorders including atypical protein assemblies as well as induced cell death. Neurodegeneration can be found in many different levels of neuronal circuitry ranging from molecular to systemic.
OMICS International through its Open access initiatives is committed to make genuine and reliable contributions to the scientific community by publishing research work and conference paper related to such disorders. It is known that OMICS Group hosts over 700 edge peer reviewed Open Access Journals which contains over 75000 eminent personalities, reputed scientists as editorial board members. Omics International organizes over more than 1000 Global Events annually with support from 1000 more scientific Societies. Its publishing group journals have over 5 million readers and the fame and success of the same can be attributed to the strong editorial board that ensure a quality and quick review process checker.
5th Neurology Congress
March 14-16, 2016 London, UK
2nd Brain Disorders Conference
October 27-29, 2016 Chicago, USA
4th Vascular Dementia Conference
June 30-July 2, 2016 Valencia, Spain
3rd Euro Psychiatry Conference
September 7-9, 2016 Amsterdam, Netherlands
May 5-6, 2016 Chicago, USA
6th World Neurological conference
May 19-21, 2016 San Antonio, USA
10th International Conference on Front temporal Dementias
31 August - 2 September 2016 Munich, Germany
The International Society of Vascular Behavioural and Cognitive Disorders Conference
12 - 15 October 2016 Amsterdam, the Netherlands
14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy
9-12 March 2016 Athens, Greece 24-28 July 2016 Toronto, Canada
Alzheimer's Association International Conference
22-28 July 2016, Toronto, Canada
31st International Conference of Alzheimer's disease International
21 - 24 April 2016 Budapest, Hungar
Neurodegenerative diseases markedly affect the lives of millions and lead to a growing public health challenge with increased costs for individuals and society. The prevention and treatment of these neurodegenerative disorders represent a critical goal of medical research today. Most of these disorders increase with age. Today, there are 25 million suffering from dementia and it is generally believed that the prevalence will be 130 million demented persons by 2050. The lack of effective treatments that can halt or reverse the disease process indicates a huge medical need.
Relevant Associations and Societies:
North American Neuromodulator Society (NANS) 18th Annual Meeting
Neurodegeneration in the ageing society
Biochemical Society & British Neuroscience Association
Pittsburgh Institute for Neurodegenerative Diseases
National Institute of Neurological Disorders and Stroke
The Institute for Neurodegenerative Disorders
North American Neuromodulation Society
Estimates of the number of people affected by Multiple Sclerosis throughout the world range between 1.1 million and 2.5 million. No data on prevalence or incidence in the EU have been systematically collected. The number of persons affected is estimated to be around 500 000 in the EU-27. In 2008, the European Commission selected the operational grant for The European Multiple Sclerosis.
Parkinson's disease is the most common neurodegenerative disorder and manifests as bradykinesia, rigidity, resting tremor and posture instability. The crude prevalence rate of PD has been reported to range from 15 per 100,000 to 12,500 per 100,000, and the incidence of PD from 15 per 100,000 to 328 per 100,000, with the disease being less common in Asian countries.
This page will be updated regularly.
This page was last updated on 11th Sep, 2015
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising